about
CLLD8/KMT1F is a lysine methyltransferase that is important for chromosome segregationOptimal management of breast cancer in the elderly patient: current perspectivesA call for specific geriatric data on cervical cancers.Chemotherapeutic errors in hospitalised cancer patients: attributable damage and extra costsAgreement for depression diagnosis between DSM-IV-TR criteria, three validated scales, oncologist assessment, and psychiatric clinical interview in elderly patients with advanced ovarian cancerAge Nutrition Chirugie (ANC) study: impact of a geriatric intervention on the screening and management of undernutrition in elderly patients operated on for colon cancer, a stepped wedge controlled trial.International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancerRole of combination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer.Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging?Biology of cancer and aging: a complex association with cellular senescence.The biology of aging and lymphoma: a complex interplay.Defining and recognising locally advanced basal cell carcinoma.Inclusion of elderly patients in oncology clinical trials.Unmet needs in the scientific approach to older patients with lymphoma.Can we predict chemo-induced hematotoxicity in elderly patients treated with pegylated liposomal doxorubicin? Results of a population-based model derived from the DOGMES phase II trial of the GINECO.Phase I dose-escalation study of intravenous aflibercept in combination with docetaxel in patients with advanced solid tumors.Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study.Etoposide pharmacokinetics and survival in patients with small cell lung cancer: a multicentre study.Advantages of prostate-specific antigen (PSA) clearance model over simple PSA half-life computation to describe PSA decrease after prostate adenomectomy.Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: results of an observational study.Impact of geriatric assessment for the therapeutic decision-making of breast cancer: results of a French survey. AFSOS and SOFOG collaborative work.Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma.Open-label uncontrolled pilot study to evaluate complementary therapy with Ruta graveolens 9c in patients with advanced cancer.Development of a geriatric vulnerability score in elderly patients with advanced ovarian cancer treated with first-line carboplatin: a GINECO prospective trial.Impact of geriatric risk factors on pegylated liposomal doxorubicin tolerance and efficacy in elderly metastatic breast cancer patients: final results of the DOGMES multicentre GINECO trial.Changes in the use of end points in clinical trials for elderly cancer patients over time.Reply to "Adherence to oral cancer therapy in older adults: The International Society of Geriatric Oncology (SIOG) taskforce recommendations" by Mislang et al.Is There an Age Threshold for Holding Off on Testing Novel Therapies?Cancer de l’ovaire : prise en charge pluridisciplinaire du cancer de l’ovaire en première ligne: Recommandations Saint-Paul-de-Vence 2016.Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.Granulocyte-colony-stimulating factor in elderly patients receiving chemotherapy for breast and gynaecological cancers: results of a French surveyCytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients[Metastatic prostate cancer treatment in the elderly][Pharmacology of anticancer drugs in the elderly: tools for dose-adjustment][Is geriatric assessment adapted to radiotherapy?][Geriatric oncology: an emergent subspecialty]Pilot study: effectiveness of a training program about autonomy in elderly patients hospitalized after an acute episodeSystematic review of care needs for older patients treated with anticancer drugsToxicity of Cancer Therapies in Older PatientsOlder and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting
P50
Q24307396-F51205D9-D3A4-4216-8404-4555DADFBE50Q27690879-B6C07F59-6C4B-4527-96F6-F840D7977CACQ31054769-C8DD95AE-B164-45F9-B4B7-55FA36908643Q34070132-16F76D75-6815-4C01-B2E0-788DB40A29BCQ35862164-CFDFBFEF-AF63-4B27-85CF-997282E7C74DQ36243265-2B94D949-7404-4CA4-AC43-E3632FB33FB6Q36925135-26407108-6FE5-4D75-A253-96F253F2AF66Q37405065-73D3A8D6-5349-4FF0-B7AE-43BDAF017607Q38185207-EA4DCD53-2A8D-4DD1-9570-B4395BF1122BQ38234858-4AA1F3B2-9B5B-497D-A4C5-F77CD71149DCQ38500035-41107E7B-B9B5-46DC-B7F6-62CD3F044F6AQ38635167-19231C7D-C5F1-4304-9A94-233C1F2D003DQ39643826-5BE7169F-F659-4498-86A0-0BAF4AEADAEBQ42344563-3511FADB-C705-44E5-B8AC-3B4A2FFED48BQ42445545-909A9F0D-6EA7-44F2-8086-6CD2AE159F49Q44813860-8BEC8B4F-6789-4E4A-91D8-85B8AB946B3FQ46236774-B571C4B1-5A12-456E-A358-A2C5A2CEAD00Q46621914-C52F4DDA-7DFF-4392-972C-8A4DDF1F60DBQ46623928-38B41586-9FE1-4393-B38F-BF50CF717185Q46982102-01982614-0694-44DF-9D40-D7EA45C06235Q47306058-CD4B6859-AB92-492E-A86F-049279584C27Q47321362-A056A675-73F9-4ADF-BC32-427F98C0F8E3Q48166997-06E3F09B-FE7C-4AE7-88CC-6D3EFD6CCD0CQ48422523-9D880B35-866B-462D-8F8D-ED675A69316FQ48466034-30BDC7C9-6A77-46CE-B0EA-599CBACBB3DFQ48582976-EBCCA78C-500E-4FA8-A3E8-8970CE39BE15Q49896273-299A3AE7-3C12-4AA8-B545-75FF462B7427Q50146471-8719CC9C-BEBC-4858-B941-4137B949E744Q52859135-4FB6C44D-B537-4072-A91F-8FD0E3AC12AFQ54390548-ED5B2047-D4C6-4E11-A04E-C4356ACAC1D2Q60685642-F5E7C659-93A1-4BD8-867C-7EFC7971933FQ80608554-9FDB1AF6-EF77-481C-B844-081DE21D5A42Q81228267-1D00321F-7926-4F6B-93BE-F847B6CD6059Q81357297-25BEB2F1-1E27-4E71-8EE4-2F23ACE5A93DQ82220407-2F041F26-9A74-4E34-BDE6-72F1F4579803Q86835883-D844F3F8-E224-4CE8-9E56-69EDB8C62667Q88143482-276C0F4B-A60F-4D06-A164-77C638118AF8Q88158658-5955F0DC-A46B-478A-9BF9-0AEA524986ADQ89083835-6953CCB5-9A8D-4E46-9DB3-2929127BA7F4Q90566090-2015D557-7EA2-48F7-8405-5483DB31A931
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Claire Falandry
@ast
Claire Falandry
@en
Claire Falandry
@es
Claire Falandry
@nl
type
label
Claire Falandry
@ast
Claire Falandry
@en
Claire Falandry
@es
Claire Falandry
@nl
prefLabel
Claire Falandry
@ast
Claire Falandry
@en
Claire Falandry
@es
Claire Falandry
@nl
P106
P31
P496
0000-0001-7267-4723